ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh - MarketWatch
ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh
LOS ANGELES, Mar 22, 2012 (BUSINESS WIRE) --
ImmunoCellular Therapeutics
IMUC
+12.14%
today announced that it has
entered into an agreement with University of Pittsburgh (Pitt) under
which Pitt has licensed to the Company intellectual property surrounding
EphA2, a tyrosine kinase receptor that is highly expressed by ovarian
cancer and other advanced and metastatic malignancies. This agreement
grants a world-wide exclusive license to the Pitt intellectual property
for ovarian and pancreatic cancers; and a world-wide non-exclusive
license to the Pitt intellectual property for brain cancer. The
financial terms of the agreement were not disclosed.
The Company will employ the Pitt intellectual property in the
development and commercialization of ICT-140, a multivalent, dendritic
cell-based vaccine for the treatment of ovarian cancer. ICT-140 is
designed to target cancer stem cells as well as daughter cells in
ovarian cancer by targeting multiple different antigens including EphA2,
mesothelin, Her-2/neu, IL-13Ra2 and several other undisclosed antigens......
